title: Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development.
abstract: The HLA class II-restricted T-cell response to hepatitis C virus (HCV) antigens is believed to influence the final outcome of hepatitis C, because it is vigorous in patients who recover from acute hepatitis C, but it is weak in those who develop a chronic infection. For this reason, exogenous stimulation of T-cell responses in chronic HCV infection may represent a strategy to cure patients with chronic hepatitis C by approximating the vigor of their T-cell reactivity to that of patients who succeed in recovering from hepatitis. It may also be a preventive approach to avoid spread of the virus by facilitating the development of a vigorous protective response at the very early stages of infection. T-cell-based vaccines composed of immunodominant, promiscuous, and conserved T-cell epitopes may represent a powerful tool to achieve optimal stimulation of the T-cell reactivity. To identify HLA class II-restricted T-cell epitopes useful for this purpose, 22 subjects with acute HCV infection were studied and followed for an average time of 29 months. Eight of them recovered from hepatitis, and 14 developed a chronic infection. Overlapping 20-mer peptides covering the entire core and NS4 antigens and a panel of peptides representing highly conserved regions of core, NS3, NS4, and NS5 were used. By direct peripheral blood T-cell stimulation and by fine-specificity analysis of HCV-specific T-cell lines and clones, highly immunogenic T-cell epitopes were identified within core, NS3, and NS4. All these epitopes are immunodominant and highly conserved among the known HCV isolates. Moreover, they are promiscuous, because they can be presented to T cells by different HLA class II molecules. Immunodominance, sequence conservation, and promiscuity make these epitopes ideal components of preventive or therapeutic T-cell-based vaccines against HCV.
authors.affiliation: Laboratorio di Immunopatologia Virale, Divisione Malattie Infettive, Azienda Ospedaliera di Parma, and Cattedra di Malattie Infettive, Università di Parma, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Lamonaca
authors.forename: G
authors.initials: G
authors.lastname: Missale
authors.forename: S
authors.initials: S
authors.lastname: Urbani
authors.forename: M
authors.initials: M
authors.lastname: Pilli
authors.forename: C
authors.initials: C
authors.lastname: Boni
authors.forename: C
authors.initials: C
authors.lastname: Mori
authors.forename: A
authors.initials: A
authors.lastname: Sette
authors.forename: M
authors.initials: M
authors.lastname: Massari
authors.forename: S
authors.initials: S
authors.lastname: Southwood
authors.forename: R
authors.initials: R
authors.lastname: Bertoni
authors.forename: A
authors.initials: A
authors.lastname: Valli
authors.forename: F
authors.initials: F
authors.lastname: Fiaccadori
authors.forename: C
authors.initials: C
authors.lastname: Ferrari
mesh_terms: D000208:Acute Disease; D000328:Adult; D015704:CD4 Antigens / Q000032:analysis*; D017124:Conserved Sequence / Q000235:genetics; D000939:Epitopes; D005260:Female; D016174:Hepacivirus / Q000235:genetics* / Q000276:immunology*; D006526:Hepatitis C / Q000503:physiopathology / Q000517:prevention & control / Q000628:therapy; D019698:Hepatitis C, Chronic / Q000503:physiopathology / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000276:immunology*; D016896:Treatment Outcome; D014761:Viral Hepatitis Vaccines
chemical_list: D015704:CD4 Antigens; D000939:Epitopes; D014761:Viral Hepatitis Vaccines